New Meta-Analysis Confirms Effectiveness of BioGaia’s Probiotic for Infant Colic

Regulatory News:

BioGaia (STO:BIOGB)

In a newly published systematic review the proof of effect on infant colic was further strengthened for L. reuteri Protectis. The review evaluated 17 studies of different treatments of infant colic, whereof L. reuteri Protectis was the only probiotic. Only one other product was deemed effective. Simethicone, a drug often prescribed for colic, was shown to have no effect.

Prior to the new review four meta-analyses, evaluating different probiotics as well as non-probiotic treatments, have come to the same conclusion; that L. reuteri Protectis is effective in colic, especially in breastfed and mixed fed infants. In the new, fifth review, with 6 studies on L. reuteri Protectis included, the proof was further strengthened.

”The new meta-analysis once again confirms our position as the number one treatment for infants with colic. Today health care professionals around the world can be totally reassured that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients”, says Peter Rothschild, President, BioGaia.

The systematic review and meta-analysis was published online by researchers Tracey Harb and colleagues at University of Queensland, Australia, in Journal of Pediatric Gastroenterology and Nutrition 14 December 2015.

Latest press releases from BioGaia

2016-01-08 BioGaia’s subsidiary IBT has US IND open and Swedish CTA¹ approved for clinical study

2015-12-01 BioGaia makes further investments in MetaboGen

2015-10-26 BioGaia signs exclusive agreement in Sri Lanka

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 11 January 2016, 11:00 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005623/en/